Form 4: Rocket Pharma GC Sells Shares for Tax Obligations
Insider Transaction Report
Rocket Pharmaceuticals General Counsel Martin Wilson sold shares to cover tax obligations related to RSU vesting.
Summary
- Martin Wilson, General Counsel of Rocket Pharmaceuticals, Inc. (RCKT), reported sales of common stock.
- On August 18, 2025, 1,004 shares were sold at a price of $3.065 per share.
- On August 19, 2025, an additional 588 shares were sold at a price of $2.996 per share.
- The sales were conducted to satisfy tax withholding obligations incurred from the vesting of Restricted Stock Units (RSUs).
- The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
- Following these transactions, Martin Wilson beneficially owns 135,462 shares of common stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine sale by an insider to cover tax obligations upon RSU vesting, often pre-planned, and does not indicate a change in sentiment towards the company.
Positives
- The sale was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction rather than a discretionary sale based on new information.
- The purpose of the sale was explicitly stated as covering tax withholding obligations related to RSU vesting, which is a common and routine event for executives.
Negatives
- An insider sale, even for tax purposes, reduces the insider's direct equity stake in the company.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Industry Context
This filing is a routine insider transaction report and does not provide broader industry context or trends. It reflects an individual executive's share activity within the biotechnology sector.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, pre-planned transaction for tax purposes and represents a relatively small portion of the insider's total holdings.
Key Dates
| Date | Description |
|---|---|
| 08/18/2025 | Transaction date for the sale of 1,004 shares of common stock. |
| 08/19/2025 | Transaction date for the sale of 588 shares of common stock. |
| 08/20/2025 | Date the Form 4 filing was signed and submitted. |
Keywords
Rocket Pharmaceuticals, RCKT, Martin Wilson, Insider Trading, Form 4, Stock Sale, RSU Vesting, General Counsel, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.